Patents by Inventor Mark W. Rixon

Mark W. Rixon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090155271
    Abstract: The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RA is a receptor for IL-17A and IL-17RC is a common receptor for both IL-17A and IL-17F. The present invention includes soluble IL-17A and IL-17F anatagonists, as well as methods for using the same.
    Type: Application
    Filed: February 12, 2009
    Publication date: June 18, 2009
    Applicant: ZYMOGENETICS, INC.
    Inventors: STEVEN D. LEVIN, MARK W. RIXON, ZEREN GAO
  • Patent number: 7501497
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Grant
    Filed: October 3, 2005
    Date of Patent: March 10, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Publication number: 20080241138
    Abstract: Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.
    Type: Application
    Filed: March 26, 2008
    Publication date: October 2, 2008
    Inventors: Steven D. Levin, Mark W. Rixon, Gao Zeren
  • Patent number: 7387780
    Abstract: A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: June 17, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Donald C. Foster, Wenfeng Xu, Karen L. Madden, James D. Kelly, Cindy A. Sprecher, Cameron S. Brandt, Mark W. Rixon, Scott R. Presnell, Brian A. Fox
  • Patent number: 7122632
    Abstract: A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: October 17, 2006
    Assignee: ZymoGenetics, Inc.
    Inventors: Donald C. Foster, Wenfeng Xu, Karen L. Madden, James D. Kelly, Cindy A. Sprecher, Cameron S. Brandt, Mark W. Rixon, Scott R. Presnell, Brian A. Fox
  • Patent number: 6641999
    Abstract: This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal VH and VL sequences which mediate TAG-72 binding and (2) human CH and CL regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human CH and CL antibody domains. The nucleotide and amino acid sequences of VH&agr;TAG VH, CC46 VH, CC49VH, CC83 VH, and CC92 VH, and CC49VL, CC83 VL, and CC92 VL idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: November 4, 2003
    Assignee: The Dow Chemical Company
    Inventors: Peter S. Mezes, Brian Gourlie, Mark W. Rixon, W. H. Kerr Anderson
  • Publication number: 20030103986
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Application
    Filed: May 20, 2002
    Publication date: June 5, 2003
    Inventors: Mark W. Rixon, Jane A. Gross
  • Patent number: 6544505
    Abstract: Interferons represent an important class of biopharmaceutical products, which have a proven track record in the treatment of a variety of medical conditions, including the treatment of certain autoimmune diseases, the treatment of particular cancers, and the enhancement of the immune response against infectious agents. To date, four types of interferons have been found in humans: interferon-&agr;, interferon-&bgr;, interferon-&ggr;, and interferon-&ohgr;. The present invention provides new forms of human and murine interferon, “interferon-&egr;,” which have applications in diagnosis and therapy.
    Type: Grant
    Filed: October 4, 2001
    Date of Patent: April 8, 2003
    Assignee: ZymoGenetics, Inc.
    Inventors: Darrell C. Conklin, Francis J. Grant, Mark W. Rixon, Wayne Kindsvogel
  • Publication number: 20030013162
    Abstract: Interferons represent an important class of biopharmaceutical products, which have a proven track record in the treatment of a variety of medical conditions, including the treatment of certain autoimmune diseases, the treatment of particular cancers, and the enhancement of the immune response against infectious agents. To date, four types of interferons have been found in humans: interferon-&agr;, interferon-&bgr;, interferon-&ggr;, and interferon-&ohgr;. The present invention provides new forms of human and murine interferon, “interferon-&egr;,” which have applications in diagnosis and therapy.
    Type: Application
    Filed: October 4, 2001
    Publication date: January 16, 2003
    Applicant: ZymoGenetics, Inc.
    Inventors: Darrell C. Conklin, Francis J. Grant, Mark W. Rixon, Wayne Kindsvogel
  • Patent number: 6329175
    Abstract: Interferons represent an important class of biopharmaceutical products, which have a proven track record in the treatment of a variety of medical conditions, including the treatment of certain autoimmune diseases, the treatment of particular cancers, and the enhancement of the immune response against infectious agents. To date, four types of interferons have been found in humans: interferon-&agr;, interferon-&bgr;, interferon-&ggr;, and interferon-&ohgr;. The present invention provides new forms of human and murine interferon, “interferon-&egr;,” which have applications in diagnosis and therapy.
    Type: Grant
    Filed: September 16, 1999
    Date of Patent: December 11, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Darrell C. Conklin, Francis J. Grant, Mark W. Rixon, Wayne Kindsvogel
  • Patent number: 6207815
    Abstract: This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal VH and VL sequences which mediate TAG-72 binding and (2) human CH and CL regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human CH and CL antibody domains. The nucleotide and amino acid sequences of VH&agr;TAG VH, CC46 VH, CC49H, CC83 VH, and CC92 VH, and CC49L, CC83 VL, and CC92 VL idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 27, 2001
    Assignee: The Dow Chemical Company
    Inventors: Peter S. Mezes, Brian B. Gourlie, Mark W. Rixon, Jeffrey Schlom, Donald A. Kaplan, W. H. Kerr Anderson
  • Patent number: 6051225
    Abstract: This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal V.sub.H and V.sub.L sequences which mediate TAG-72 binding and (2) human C.sub.H and C.sub.L regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C.sub.H and C.sub.L antibody domains. The nucleotide and amino acid sequences of V.sub.H .alpha.TAG V.sub.H, CC46 V.sub.H, CC49.sub.H, CC83 V.sub.H, and CC92 V.sub.H, and CC49.sub.L, CC83 V.sub.L, and CC92 V.sub.L idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.
    Type: Grant
    Filed: March 31, 1993
    Date of Patent: April 18, 2000
    Assignee: The Dow Chemical Company
    Inventors: Peter S. Mezes, Brian B. Gourlie, Mark W. Rixon, Jeffrey Schlom, Donald A. Kaplan, W. H. Kerr Anderson
  • Patent number: 5993813
    Abstract: This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal V.sub.H and V.sub.L sequences which mediate TAG-72 binding and (2) human C.sub.H and C.sub.L regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C.sub.H and C.sub.L antibody domains. The nucleotide and amino acid sequences of V.sub.H .alpha.TAG V.sub.H, CC46 V.sub.H, CC49.sub.H, CC83 V.sub.H, and CC92 V.sub.H, and CC49.sub.L, CC83 V.sub.L, and CC92 V.sub.L idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: November 30, 1999
    Assignee: The Dow Chemical Company
    Inventors: Peter S. Mezes, Brian B. Gourlie, Mark W. Rixon, Jeffrey Schlom, Donald A. Kaplan, W. H. Kerr Anderson
  • Patent number: 5808033
    Abstract: The present invention discloses novel chimeric monoclonal antibodies directed against human carcinoembryonic antigen, having antigen-specific variable regions. DNA constructs for the light and heavy chain variable regions comprising the novel antibodies of the invention are also disclosed. Eukaryotic host cells capable of expression of the chimeric antibodies and comprising the novel chimeric antibody-encoding DNA constructs are also described.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 15, 1998
    Assignee: The Dow Chemical Company
    Inventors: Brian B. Gourlie, Mark W. Rixon, Peter S. Mezes
  • Patent number: 5472693
    Abstract: The present invention discloses novel chimeric monoclonal antibodies directed against human carcinoembryonic antigen, having antigen-specific variable regions. DNA constructs for the light and heavy chain variable regions comprising the novel antibodies of the invention are also disclosed. Eukaryotic host cells capable of expression of the chimeric antibodies and comprising the novel chimeric antibody-encoding DNA constructs are also described.
    Type: Grant
    Filed: February 16, 1993
    Date of Patent: December 5, 1995
    Assignees: The Dow Chemical Company, National Institutes of Health
    Inventors: Brian B. Gourlie, Mark W. Rixon, Peter S. Mezes, Donald A. Kaplan, Jeffrey Schlom